While it is possible that metastatic prostate incidence may stabilize or decrease with advances in imaging modalities, prostate MRI or prostate-specific membrane antigen PET (2018) could increase incidence of lower stage prostate cancer via improved prognostication28,29. This evidence concerns the gene FOLH1 and prostate cancer.